Investigational Drug
AZD9574
TrialFetch AI Analysis
Show TrialFetch AI Analysis
Overview
Palacaparib (AZD9574) is an investigational, oral cancer drug designed to reach the brain. It is being studied alone and with other treatments in the phase I/IIa CERTIS1 trial for advanced solid tumors, including breast cancer with brain metastases and IDH-mutant glioma. No human efficacy or safety results were identified in the available trial reports, so response rates and adverse-event rates cannot yet be summarized. (plpl.www.astrazenecaclinicaltrials.com)
Mechanism of action
AZD9574 selectively inhibits PARP1, a protein involved in DNA repair, and traps it on damaged DNA. Laboratory and animal studies found that it crosses the blood–brain barrier and showed antitumor activity in models with deficient homologous-recombination repair. Those preclinical findings do not establish benefit or safety in people. (pubmed.ncbi.nlm.nih.gov)
Further reading
- Preclinical characterization of AZD9574 (pubmed.ncbi.nlm.nih.gov)
- CERTIS1 trial description (plpl.www.astrazenecaclinicaltrials.com)
Last updated: Sep 2026
Active trials using AZD9574
Found 4 active trials using this drug:
TrialFetch AI summary: Adults with progressive, PSMA-positive metastatic castration-resistant prostate cancer after one novel androgen receptor pathway inhibitor receive AZD2265, a PSMA-targeted actinium-225 radioligand, plus AZD9574, an oral PARP1 inhibitor. Dose expansion compares the combination with AZD2265 alone and docetaxel.
ClinicalTrials.gov ID: NCT07590934
TrialFetch AI summary: This study enrolls patients with progressing metastatic castration-resistant prostate adenocarcinoma, ECOG performance status 0–1, and adequate organ function. It evaluates AZD0516, a STEAP2-directed antibody–drug conjugate delivering the topoisomerase I inhibitor exatecan, alone or with AZD9574 (palacaparib), a PARP1 inhibitor.
ClinicalTrials.gov ID: NCT07181161
TrialFetch AI summary: Adults with previously treated advanced solid tumors, measurable disease, and ECOG performance status 0–1 receive AZD5335, a folate receptor alpha–targeted antibody–drug conjugate delivering a topoisomerase I inhibitor. It is studied alone or with the PARP1 inhibitors saruparib or AZD9574, bevacizumab, or carboplatin with or without bevacizumab; module-specific eligibility may apply.
ClinicalTrials.gov ID: NCT05797168
TrialFetch AI summary: Patients with advanced solid tumors are enrolled in biomarker- and tumor-specific cohorts, including homologous-recombination-repair–mutated breast, ovarian, pancreatic or castration-resistant prostate cancer; recurrent IDH-mutant glioma; HER2-expressing or HER2-mutant tumors; and previously treated triple-negative breast, endometrial, ovarian or prostate cancer. They receive the brain-penetrant, PARP1-selective inhibitor palacaparib (AZD9574) alone or with temozolomide, the HER2-directed antibody–drug conjugate trastuzumab deruxtecan, or the TROP2-directed antibody–drug conjugate datopotamab deruxtecan.
ClinicalTrials.gov ID: NCT05417594
